



GOVERNMENT OF ODISHA  
HEALTH & FAMILY WELFARE DEPARTMENT

\*\*\*\*\*

File No. HFW-SCH-I-COVID-0057-2020 15290 /H Dated, 20-5-2021

From

Shri P. K. Mohapatra, IAS,  
Additional Chief Secretary to Government

To

The Dean & Principal/Superintendent, SCB MCH, Cuttack  
The Dean & Principal/Superintendent, MKCG MCH, Berhampur  
The Director/Superintendent, VIMSAR, Burla  
The Dean & Principal/Superintendent, SLN MCH, Koraput  
The Director, Capital Hospital, Bhubaneswar  
The Director, IGH Hospital, Rourkela

**Sub:- Discontinuation of Plasma Therapy in the State - Reg.**

Madam/Sir,

I am to enclose herewith a copy of the guideline issued by MoHFW, Gol dated 19.05.2021 and to say that the guideline has deleted the use of Convalescent Plasma Therapy for treatment of COVID-19 infection.

The Technical Committee comprising of DPH(O), DHS(O) and DMET(O) has reported the following points:


1. AIIMS / ICMR- COVID-19 National Task Force / Joint Monitoring Group (Dte.GHS), MoHFW, Gol has issued new clinical guidelines for management of Covid-19 patients from which they have deleted Convalescent Plasma Therapy included as 'off-label' therapy .
2. The results of the RECOVERY clinical trial published in The Lancet on May 14. Researchers who conducted the trial reported that transfusions of high-titre plasma (i.e. plasma with a higher quantity of antibodies) didn't improve the recipient's chances of survival after 28 days.
3. Until May 17, ICMR had included the use of convalescent plasma for "off-label", or unapproved, use, despite the findings of its own trial. (Some doctors had also expressed dissatisfaction with parts of this trial, including poor patient selection and lack of plasma standardization.)
4. In the absence of other treatment guidelines, its inclusion in ICMR's protocols allowed doctors and hospitals following varying treatment regimes around the

country, drawn from their own experiences, to prescribe the use of convalescent plasma as well despite zero supporting evidence.

5. The Committee has pointed out that international guideline such as those from the US National Institutes of Health and the IDSA guidelines also recommend against general use of plasma therapy for COVID-19.

It is therefore, instructed to all concerned to adhere to the guideline of MoHFW, GOI and discontinue convalescent plasma therapy for the management of COVID-19 infection in the State until further orders.

Yours faithfully,

  
Additional Chief Secretary to Government

Memo No. 15291 /H

Dated, 20-5-2021

Copy forwarded to Dr. Smita Mahapatra, Associate Professor, Transfusion Medicine, SCB MCH, Cuttack/ Dr. Debasis Mishra, Blood Bank Officer, Capital Hospital, Bhubaneswar for information and necessary action.

  
Deputy Secretary to Government

Memo No. 15292 /H

Dated, 20-5-2021

Copy forwarded all Collector & District Magistrates/ all CDM & PHOs/ all Municipal Commissioners for information and necessary action.

  
Deputy Secretary to Government

Memo No. 15293 /H

Dated, 20-5-2021

Copy forwarded to all Director under Health & Family Welfare Department / MD, NHM, Bhubaneswar, Odisha / MD, OSMCL, Bhubaneswar/ Director, Blood Safety, Bhubaneswar for information and necessary action.

  
Deputy Secretary to Government



**AIIMS/ ICMR-COVID-19 National Task Force/Joint  
Monitoring Group (Dte.GHS)  
Ministry of Health & Family Welfare, Government of India  
CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS**

19th May 2021

